CERo Therapeutics (NASDAQ:CERO) Earns Buy Rating from Analysts at D. Boral Capital

D. Boral Capital assumed coverage on shares of CERo Therapeutics (NASDAQ:CERO) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $11.00 price target on the stock.

CERo Therapeutics Stock Up 13.6 %

Shares of CERO stock traded up $0.09 during trading hours on Tuesday, hitting $0.73. 422,273 shares of the company were exchanged, compared to its average volume of 448,323. CERo Therapeutics has a 52 week low of $0.53 and a 52 week high of $171.00. The business has a 50 day moving average of $1.13 and a two-hundred day moving average of $6.15.

Hedge Funds Weigh In On CERo Therapeutics

Several hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC acquired a new position in CERo Therapeutics during the first quarter worth $161,000. Avantax Planning Partners Inc. boosted its stake in shares of CERo Therapeutics by 89.9% during the 4th quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock worth $155,000 after buying an additional 1,224,021 shares during the last quarter. Finally, ARCH Venture Management LLC increased its position in shares of CERo Therapeutics by 550.4% in the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after acquiring an additional 7,949,265 shares during the last quarter. 29.64% of the stock is owned by institutional investors.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.